Cystic Fibrosis (CF)

We lead research and treatment efforts for cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. Clinical researchers play a pivotal role in conducting groundbreaking clinical trials that support revolutionary advances in treatments, transforming what was once a fatal disease into one where most individuals with CF can now live normal lifespans. Our programs are focused on advancing our understanding of CF, improving treatments and enhancing the quality of life for those affected by the disease. Here is an overview of our CF research programs:

• Adult Cystic Fibrosis Research Center: Understanding the genetic and environmental factors of cystic fibrosis, developing new treatments and improving care strategies for managing the disease.
• Lung Inflammation and Infection Research: Our research focuses on understanding and treating lung inflammation and bacterial infections in people with cystic fibrosis, including bronchiectasis, epidemiology, pathogenesis, diagnostics and treatment strategies.
• Collaborative Research: We collaborate with other institutions, pharmaceutical companies and the Cystic Fibrosis Foundation to enhance the scope and impact of our research. This includes multicenter studies and joint research initiatives.
• Clinical Trials and Novel Diagnostics and Treatments: At National Jewish Health, we are involved in clinical trials testing new drugs, biologics and other treatments for CF. Research includes developing strategies to manage symptoms, improve adherence to treatment and support overall health and well-being.
• Cystic Fibrosis Research Advancements: Clinical trials for approvals of Trikafta that has dramatically improved survival and lung function in people with CF. Novel use of bacteriophages to treat non-tuberculosis mycobacterial lung infection in people with CF.